{"classes":[{"categories":[{"measurements":[{"comment":"Here, NA signifies that median and confidence interval was not estimable due to less number of events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Here, NA signifies that median and confidence interval was not estimable due to less number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"OS is defined as the time between randomization and death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 15 milligram per kilogram (mg/kg) of siltuximab as a 1-hour intravenous (IV) infusion every 4 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or the end of the study (up to 4 years after randomization of the last participant).","id":"OG000","title":"Siltuximab"},{"description":"Participants received placebo as a 1-hour IV infusion every 4 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or the end of the study (up to 4 years after randomization of the last participant).","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"ITT population included participants who were randomly assigned to siltuximab or placebo treatment group based on an IVRS.","reportingStatus":"POSTED","timeFrame":"Up to 4.7 Years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Days"}